City File: Minnow leaps

MINNOW of the week was Haemocell, which more than doubled to 210p on news that the tiny pharmaceutical company had won US approval for its blood filtration machine. The shares had been low partly because of the losses incurred on development costs. As a latecomer to the market, however, it still represents a relatively risky investment. Keep clear, but watch for the chance to get in on any relapse.